Jpmorgan Chase & CO Chimerix Inc Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Chimerix Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,440 shares of CMRX stock, worth $23,310. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,440
Previous 1,539
188.5%
Holding current value
$23,310
Previous $1,000
1400.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CMRX
# of Institutions
77Shares Held
40.3MCall Options Held
243KPut Options Held
110K-
Ra Capital Management, L.P. Boston, MA8.8MShares$46.2 Million0.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.04MShares$21.2 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.77MShares$19.8 Million0.32% of portfolio
-
Monaco Asset Management Sam2.82MShares$14.8 Million1.45% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.56MShares$13.4 Million0.0% of portfolio
About CHIMERIX INC
- Ticker CMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,622,896
- Market Cap $460M
- Description
- Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...